Carly L. Lancaster

Carly L. Lancaster

Auto-generated profile, based on publicly available information

Carly L. Lancaster

Teiko United States

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Molecular Biology of the Cell
Verified
Journal Article
Closed access
CLCarly L. Lancaster
Carly L. Lancaster
PYPranav S. Yalamanchili
Pranav S. Yalamanchili
JGJordan N. Goldy
Jordan N. Goldy
SLSara W. Leung
Sara W. Leung
ACAnita H. Corbett
Anita H. Corbett
KMKenneth H. Moberg
Kenneth H. Moberg
The Drosophila RNA-binding protein (RBP) Nab2 acts in neurons to regulate neurodevelopment and is orthologous to the human intellectual disability-linked RBP, ZC3H14. Nab2 governs axon projection in mushroom body neurons and limits dendritic arborization of class IV sensory neurons in part by regulating splicing events in ∼150 mRNAs. Analysis of the Sex-lethal ( Sxl) mRNA revealed that Nab2 promotes an exon-skipping event and regulates m6A methylation on Sxl pre-mRNA by the Mettl3 methyltransferase. Mettl3 heterozygosity broadly rescues Nab2null phenotypes implying that Nab2 acts through similar mechanisms on other RNAs, including unidentified targets involved in neurodevelopment. Here, we show that Nab2 and Mettl3 regulate the removal of a 5′UTR (untranslated region) intron in the trio pre-mRNA. Trio utilizes two GEF domains to balance Rac and RhoGTPase activity. Intriguingly, an isoform of Trio containing only the RhoGEF domain, GEF2, is depleted in Nab2null nervous tissue. Expression of Trio-GEF2 rescues projection defects in Nab2null axons and dendrites, while the GEF1 Rac1-regulatory domain exacerbates these defects, suggesting Nab2-mediated regulation Trio-GEF activities. Collectively, these data indicate that Nab2-regulated processing of trio is critical for balancing Trio-GEF1 and -GEF2 activity and show that Nab2, Mettl3, and Trio function in a common pathway that shapes axon and dendrite morphology.

6 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
CLCarly L. Lancaster
Carly L. Lancaster
PYPranav S. Yalamanchili
Pranav S. Yalamanchili
JGJordan N. Goldy
Jordan N. Goldy
SLSara W. Leung
Sara W. Leung
ACAnita H Corbett
Anita H Corbett
KMKenneth H. Moberg
Kenneth H. Moberg
The Drosophila RNA binding protein (RBP) Nab2 acts in neurons to regulate neurodevelopment and is orthologous to the human intellectual disability-linked RBP, ZC3H14. Nab2 governs axon projection in mushroom body neurons and limits dendritic arborization of class IV sensory neurons in part by regulating splicing events in ~150 mRNAs. Analysis of the Sex-lethal ( Sxl ) mRNA revealed that Nab2 promotes an exon-skipping event and regulates m 6 A methylation on Sxl pre-mRNA by the Mettl3 methyltransferase. Mettl3 heterozygosity broadly rescues Nab2 null phenotypes implying that Nab2 acts through similar mechanisms on other RNAs, including unidentified targets involved in neurodevelopment. Here, we show that Nab2 and Mettl3 regulate the removal of a 5’UTR intron in the trio pre-mRNA. Trio utilizes two GEF domains to balance Rac and RhoGTPase activity. Intriguingly, an isoform of Trio containing only the RhoGEF domain, GEF2, is depleted in Nab2 null nervous tissue. Expression of Trio-GEF2 rescues projection defects in Nab2 null axons and dendrites, while the GEF1 Rac1-regulatory domain exacerbates these defects, suggesting Nab2-mediated regulation Trio-GEF activities. Collectively, these data identify Nab2-regulated splicing as a key step in balancing Trio GEF1 and GEF2 activity and show that Nab2, Mettl3, and Trio function in a common pathway that shapes axon and dendrite morphology. Significance Statement: Drosophila Nab2, ortholog of the human RBP ZC3H14 mutated in inherited intellectual disability, acts through unknown RNA targets to control axon and dendrite morphology. This study shows that Nab2 and the Mettl3 methyltransferase guide splicing of trio mRNA, which encodes a conserved GEF-domain protein. Intron retention in trio mRNA leads to an imbalance in levels of two Trio GEF domains in Nab2-deficient neurons and restoring this balance rescues neuronal defects. The authors conclude that Nab2 control of trio splicing is required to pattern axon and dendrite growth and suggests that ZC3H14 may play a similar role in the vertebrate brain.

13 October 2026 in Bioanalysis
Verified
Journal Article
Open access
MLMichael Lahn
Michael Lahn
GCGiusy Di Conza
Giusy Di Conza
KMKristina Magee
Kristina Magee
SMSacha Martiny
Sacha Martiny
CLCarly Lancaster
Carly Lancaster
RSRamji Srinivasan
Ramji Srinivasan

29 August 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAlex Seok Choi
Alex Seok Choi
LJLaura M Jenkins-Lane
Laura M Jenkins-Lane
WBWade Barton
Wade Barton
AKAsha Kumari
Asha Kumari
CLCarly Lancaster
Carly Lancaster
KMKarthikeyan Mythreye
Karthikeyan Mythreye
In pathologies such as cancer, aberrant Transforming Growth Factor-β (TGF-β) signaling exerts profound tumor intrinsic and extrinsic consequences. Intense clinical endeavors are underway to target this pivotal pathway. Central to the success of these interventions is pinpointing factors that decisively modulate the TGF-β responses. Betaglycan/type III TGF-β receptor (TβRIII), is an established co-receptor for the TGF-β superfamily known to bind directly to TGF-βs 1-3 and inhibin A/B. While betaglycan can be membrane-bound, it can also undergo ectodomain cleavage to produce soluble-betaglycan that can sequester its ligands. The extracellular domain of betaglycan undergoes heparan sulfate and chondroitin sulfate glycosaminoglycan modifications, transforming betaglycan into a proteoglycan. Here we report the unexpected discovery that the heparan sulfate modifications are critical for the ectodomain shedding of betaglycan. In the absence of such modifications, betaglycan is not shed. Such shedding is indispensable for the ability of betaglycan to suppress TGF-β signaling and the cells’ responses to exogenous TGF-β ligands. Using unbiased transcriptomics, we identified TIMP3 as a key regulator of betaglycan shedding and thereby TGF-β signaling. Our results bear significant clinical relevance as modified betaglycan is present in the ascites of patients with ovarian cancer and can serve as a marker for predicting patient outcomes and TGF-β signaling responses. These studies are the first to demonstrate a unique reliance on the glycosaminoglycan modifications of betaglycan for shedding and influence on TGF-β signaling responses. Dysregulated shedding of TGF-β receptors plays a vital role in determining the response and availability of TGF-βs’, which is crucial for prognostic predictions and understanding of TGF-β signaling dynamics.